PL2407155T3 - Formulacje inekalcytolu - Google Patents

Formulacje inekalcytolu

Info

Publication number
PL2407155T3
PL2407155T3 PL11173860T PL11173860T PL2407155T3 PL 2407155 T3 PL2407155 T3 PL 2407155T3 PL 11173860 T PL11173860 T PL 11173860T PL 11173860 T PL11173860 T PL 11173860T PL 2407155 T3 PL2407155 T3 PL 2407155T3
Authority
PL
Poland
Prior art keywords
inecalcitol
formulations
Prior art date
Application number
PL11173860T
Other languages
English (en)
Inventor
Rémi Delansorne
Original Assignee
Hybrigenics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/836,974 external-priority patent/US20120015913A1/en
Priority claimed from EP10305783A external-priority patent/EP2407152A1/en
Application filed by Hybrigenics Sa filed Critical Hybrigenics Sa
Publication of PL2407155T3 publication Critical patent/PL2407155T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11173860T 2010-07-15 2011-07-13 Formulacje inekalcytolu PL2407155T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/836,974 US20120015913A1 (en) 2010-07-15 2010-07-15 Formulations of 14-EPI-Analogues of Vitamin D
EP10305783A EP2407152A1 (en) 2010-07-15 2010-07-15 Formulations of 14-epi-analogues of vitamin D
EP11173860A EP2407155B1 (en) 2010-07-15 2011-07-13 Formulations of inecalcitol

Publications (1)

Publication Number Publication Date
PL2407155T3 true PL2407155T3 (pl) 2013-05-31

Family

ID=44281019

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11173836T PL2407154T3 (pl) 2010-07-15 2011-07-13 Formulacje 14-epi-analogów witaminy D
PL11173860T PL2407155T3 (pl) 2010-07-15 2011-07-13 Formulacje inekalcytolu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11173836T PL2407154T3 (pl) 2010-07-15 2011-07-13 Formulacje 14-epi-analogów witaminy D

Country Status (18)

Country Link
EP (2) EP2407155B1 (pl)
JP (2) JP5836372B2 (pl)
KR (2) KR101821440B1 (pl)
CN (2) CN103096876A (pl)
AU (2) AU2011278346B2 (pl)
BR (2) BR112013000930A2 (pl)
CA (2) CA2805198C (pl)
DK (2) DK2407155T3 (pl)
ES (2) ES2401715T3 (pl)
HR (2) HRP20130093T1 (pl)
IL (2) IL224191A (pl)
MX (1) MX2013000539A (pl)
NZ (2) NZ606679A (pl)
PL (2) PL2407154T3 (pl)
PT (2) PT2407155E (pl)
SG (2) SG187072A1 (pl)
SI (2) SI2407155T1 (pl)
WO (3) WO2012007512A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011278346B2 (en) * 2010-07-15 2016-04-07 Hybrigenics Sa New formulations of 14 - epi -analogues of vitamin D
US20120015913A1 (en) 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
EP2908827A4 (en) * 2012-10-19 2016-08-31 Celus Pharmaceuticals Inc VITAMIN D ANALOGUE FOR THE TREATMENT OF A NEUROLOGICAL DISEASE
WO2015193480A1 (en) * 2014-06-19 2015-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition comprising a combination of dna methylation inhibitor and a vitamin d receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse
NZ749389A (en) * 2016-06-08 2022-12-23 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699200B2 (en) 1993-07-09 1998-11-26 Roger Bouillon Novel structural analogues of vitamin D
JPH10111593A (ja) * 1996-10-04 1998-04-28 Asahi Optical Co Ltd 複写機の変倍光学装置
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
GB0305332D0 (en) 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7332482B2 (en) 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
GB0423091D0 (en) * 2004-10-19 2004-11-17 Leuven K U Res & Dev Bioactive vitamin d analogues
US20070093458A1 (en) * 2005-07-18 2007-04-26 Anchel Schwartz Preparation of paricalcitol and crystalline forms thereof
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
JP2010111593A (ja) * 2008-11-04 2010-05-20 Teijin Pharma Ltd 14−エピ−19−ノルプレビタミンd3誘導体
NZ596497A (en) * 2009-05-20 2013-05-31 Hybrigenics Sa New therapeutical uses of inecalcitol
AU2011278346B2 (en) * 2010-07-15 2016-04-07 Hybrigenics Sa New formulations of 14 - epi -analogues of vitamin D

Also Published As

Publication number Publication date
IL224191A (en) 2016-03-31
WO2012007570A2 (en) 2012-01-19
AU2011278346B2 (en) 2016-04-07
BR112013000930A2 (pt) 2017-10-31
RU2013106492A (ru) 2014-08-20
RU2013106493A (ru) 2014-08-20
IL224192A (en) 2016-02-29
AU2011278352A1 (en) 2013-03-07
CN103096877A (zh) 2013-05-08
HRP20130093T1 (hr) 2013-02-28
HRP20130237T1 (hr) 2013-04-30
KR20130089249A (ko) 2013-08-09
DK2407155T3 (da) 2013-04-02
PT2407154E (pt) 2013-02-15
SG187071A1 (en) 2013-02-28
ES2401715T3 (es) 2013-04-23
AU2011278346A1 (en) 2013-03-07
KR101821440B1 (ko) 2018-01-23
PL2407154T3 (pl) 2013-04-30
SG187072A1 (en) 2013-03-28
BR112013000941A2 (pt) 2017-10-31
DK2407154T3 (da) 2013-03-04
EP2407155B1 (en) 2012-12-26
WO2012007517A1 (en) 2012-01-19
SI2407155T1 (sl) 2013-04-30
KR101821441B1 (ko) 2018-01-23
ES2398640T3 (es) 2013-03-20
EP2407154A1 (en) 2012-01-18
CN103096877B (zh) 2017-09-22
JP2013531024A (ja) 2013-08-01
WO2012007570A3 (en) 2012-05-24
WO2012007512A1 (en) 2012-01-19
JP5836373B2 (ja) 2015-12-24
CA2805203A1 (en) 2012-01-19
PT2407155E (pt) 2013-04-03
EP2407155A1 (en) 2012-01-18
SI2407154T1 (sl) 2013-03-29
JP2013531023A (ja) 2013-08-01
EP2407154B1 (en) 2012-11-07
AU2011278352B2 (en) 2016-07-21
NZ606679A (en) 2014-07-25
NZ606678A (en) 2014-11-28
CA2805198A1 (en) 2012-01-19
MX2013000539A (es) 2013-04-11
CN103096876A (zh) 2013-05-08
CA2805198C (en) 2018-07-31
JP5836372B2 (ja) 2015-12-24
KR20130103709A (ko) 2013-09-24

Similar Documents

Publication Publication Date Title
PL2528602T5 (pl) Preparaty bendamustyny
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
IL237604A0 (en) Compositions of enzalutamide
SI2640893T2 (sl) Sestavki
SI2407155T1 (sl) Preparati na osnovi inekalcitola
EP2552210A4 (en) FORMULAS FROM MAZINDOL
ZA201300194B (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
ZA201300196B (en) Formulations
GB201018648D0 (en) Formulations
GB201007702D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201018649D0 (en) Formulations
GB201008358D0 (en) Formulations
GB201018645D0 (en) Formulations
GB201010494D0 (en) Formulations
GB201007959D0 (en) Formulations
GB201018647D0 (en) Formulations
GB201012589D0 (en) Formulations
GB201005587D0 (en) Novel formulations
HU1000688D0 (en) Use of trifluoro-phal
TWM390349U (en) Structure of door-in-door
TWM386865U (en) Residue-filtering structure of juice-extractor
TWM388315U (en) Improved structure of hemoclip